View Older Stories View More Recent Stories

Aug 2, 2022 04:01PM Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Jul 29, 2022 07:05AM Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022
Jul 12, 2022 07:05AM Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jun 30, 2022 07:05AM Forma Therapeutics Holdings (FMTX) Announces Executive Appoitments
Jun 30, 2022 07:05AM Forma Therapeutics Announces Appointment of New Executive Team Members
Jun 10, 2022 07:22AM Forma Therapeutics Announces Presentations at Upcoming Hematology Conferences
Jun 3, 2022 07:05AM Forma Therapeutics to Present at the Jefferies Healthcare Conference
May 26, 2022 07:09AM Forma Therapeutics Holdings (FMTX) Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline
May 26, 2022 07:05AM Forma Therapeutics Highlights Etavopivat Development Expansion and Introduces New Oncology Program from Research Pipeline at Inaugural Research and Development (R&D) Day
May 6, 2022 07:05AM Forma Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 29, 2022 07:05AM Forma Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 6, 2022
Mar 1, 2022 07:05AM Forma Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
Feb 23, 2022 07:05AM Forma Therapeutics to Report Fourth Quarter and Year-end 2021 Financial Results and Provide Business Update on March 1, 2022
Feb 8, 2022 07:05AM Forma Therapeutics to Present at 11th Annual SVB Leerink Healthcare Conference
Jan 13, 2022 07:06AM Forma Therapeutics Holdings (FMTX) Appoints Arturo Molina to its Board
Jan 13, 2022 07:05AM Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee
Jan 7, 2022 07:05AM Forma Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
Dec 16, 2021 07:10AM Forma Therapeutics' (FMTX) Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 AML
Dec 16, 2021 07:05AM Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia
Dec 11, 2021 09:30AM Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease
Dec 9, 2021 07:05AM Forma Therapeutics Launches formabridge and $1M Grants Program to Support Transition from Pediatric to Adult Care in Sickle Cell Disease
Nov 30, 2021 07:05AM  Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
Nov 12, 2021 07:05AM Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 5, 2021 07:05AM Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
Nov 4, 2021 09:05AM Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
Oct 7, 2021 07:06AM Forma Therapeutics (FMTX) FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Can
Oct 7, 2021 07:05AM Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
Sep 17, 2021 07:05AM Forma Therapeutics to Participate in Upcoming Investor Conferences
Aug 13, 2021 07:05AM Forma Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 6, 2021 07:05AM Forma Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 13, 2021
Jun 14, 2021 07:08AM Forma Therapeutics Holdings (FMTX) Names John E. Bishop, Ph.D. CTO
Jun 14, 2021 07:05AM Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
Jun 11, 2021 07:07AM Forma Therapeutics Holdings (FMTX) New Phase 1 Data on Etavopivat at EHA
Jun 11, 2021 07:05AM Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
May 20, 2021 07:13AM Forma Therapeutics Holdings (FMTX) to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO
May 20, 2021 07:05AM Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
May 17, 2021 07:05AM Forma Therapeutics to Participate in Upcoming Investor Conferences
May 14, 2021 07:05AM Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 6, 2021 07:05AM Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
Mar 30, 2021 07:20AM Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update
Mar 30, 2021 07:08AM Forma Therapeutics Holdings (FMTX) Reports Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting Doses Being Evaluated in Phase 2/3 Registrational Trial
Mar 30, 2021 07:05AM Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study
Mar 23, 2021 04:05PM Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Feb 17, 2021 07:05AM Forma Therapeutics to Participate in Upcoming Investor Conferences
Jan 20, 2021 07:07AM Forma Therapeutics Holdings (FMTX) Reports First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051
Jan 20, 2021 07:05AM Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
Jan 11, 2021 07:06AM Forma Therapeutics (FMTX) Reviews 2020 Highlights and Outlines Key 2021 Milestones
Jan 11, 2021 07:05AM Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
Jan 7, 2021 07:05AM Forma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of Directors
Dec 7, 2020 04:40PM Forma Therapeutics Holdings (FMTX) Highlights Proof-of-Concept Data for Phase 1 Trial of FT-4202
View More Recent Stories View Older Stories